Loading
Dual immunotherapy with nivolumab and ipilimumab delayed progression more than nivolumab alone across all lines of treatment in microsatellite-unstable colorectal cancer, with about seven in ten patients progression-free at three years.
Phase 3 trial of 707 patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer randomised to nivolumab plus ipilimumab, nivolumab alone or chemotherapy; this report compares the two immunotherapy arms across all lines.
Progression-free survival favoured the combination (hazard ratio 0.62; three-year rate about 68 versus 51 percent) with a higher response rate (71 versus 58 percent); grade 3 to 4 treatment-related adverse events were 22 versus 14 percent.
Nivolumab-ipilimumab is a first-line standard for microsatellite-unstable metastatic colorectal cancer alongside pembrolizumab, with the trade-off of more immune toxicity for deeper and more durable control.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Ipilimumab, Nivolumab.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Ipilimumab, Nivolumab.
Shares The Lancet, Ipilimumab, Nivolumab.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Ipilimumab, Nivolumab.
Shares CheckMate 8HW, Mismatch-repair deficient (MSI-high) colorectal cancer, Ipilimumab, Nivolumab.
Shares Ipilimumab, Nivolumab.
Shares Ipilimumab, Nivolumab.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab.